A phase I dose finding and dose expansion study for CYTO NK 202 in B cell malignancies
Latest Information Update: 17 Mar 2021
Price :
$35 *
At a glance
- Drugs CYTO NK 202 (Primary)
- Indications B-cell leukaemia; B-cell lymphoma
- Focus Adverse reactions
- 17 Mar 2021 New trial record